v3.26.1
Condensed Consolidated Statements of Equity (Deficit) (Unaudited) - USD ($)
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Noncontrolling Interest [Member]
Retained Earnings [Member]
Balance at Dec. 31, 2024 $ (9,013,430) $ 129,697,784 $ (1,198,286) $ (137,512,928)
Balance, shares at Dec. 31, 2024   214      
Stock-based compensation 13,824   13,824    
Sale of common stock and pre-funded warrants, net of offering costs 14,308,300 14,308,300    
Sale of common stock and pre-funded warrants, net of offering costs, shares   262      
Issuance of common stock upon exercise of pre-funded warrants $ 3 (3)    
Issuance of common stock upon exercise of pre-funded warrants, shares   3,272      
Fair value of pre-funded warrants issued along with sale of common stock (1,803) (1,803)    
Transition of warrant derivative liability to equity upon exercise of pre-funded warrants 1,803 1,803    
Issuance of common stock upon exercise of June 2024 Series B common stock purchase warrants 3,793 3,793    
Issuance of common stock upon exercise of June 2024 Series B common stock purchase warrants   126      
Transition of warrant derivative liability to equity upon exercise of Series B warrants 1,989,806 1,989,806
Net income (loss) 4,267,082 3,611 4,263,471
Balance at Mar. 31, 2025 11,569,375 $ 3 146,013,504 (1,194,675) (133,249,457)
Balance, shares at Mar. 31, 2025   3,874      
Balance at Dec. 31, 2024 (9,013,430) 129,697,784 (1,198,286) (137,512,928)
Balance, shares at Dec. 31, 2024   214      
Transition to additional paid-in capital upon conversion of convertible notes        
Net income (loss) (222,122)        
Balance at Jun. 30, 2025 8,151,705 $ 115 147,084,926 (1,138,678) (137,794,658)
Balance, shares at Jun. 30, 2025   115,162      
Balance at Dec. 31, 2024 (9,013,430) 129,697,784 (1,198,286) (137,512,928)
Balance, shares at Dec. 31, 2024   214      
Balance at Dec. 31, 2025 2,369,956 $ 138 148,440,056 (1,885,802) (144,184,436)
Balance, shares at Dec. 31, 2025   138,004      
Balance at Mar. 31, 2025 11,569,375 $ 3 146,013,504 (1,194,675) (133,249,457)
Balance, shares at Mar. 31, 2025   3,874      
Stock-based compensation 9,741 9,741
Net income (loss) (4,489,204) 55,997 (4,545,201)
Fair value of Series A warrants issued along with sale of common stock (1,340,214) (1,340,214)
Fair value of Series B warrants issued along with sale of common stock (5,406,408) (5,406,408)
Issuance of common stock upon exercise of February 2025 Series B common stock purchase warrants $ 112 (112)
Issuance of common stock upon exercise of February 2025 Series B common stock purchase warrants, shares   111,288      
Transition of warrant derivative liability to equity upon exercise of Series B warrants issued along with February 2025 sale of common stock 5,406,320 5,406,320
Transition of warrant derivative liability to equity of Series A warrants issued along with February 2025 sale of common stock 530,101 530,101
Deemed capital contribution related to modification of notes payable - related party 1,871,994 1,871,994
Balance at Jun. 30, 2025 8,151,705 $ 115 147,084,926 (1,138,678) (137,794,658)
Balance, shares at Jun. 30, 2025   115,162      
Balance at Dec. 31, 2025 2,369,956 $ 138 148,440,056 (1,885,802) (144,184,436)
Balance, shares at Dec. 31, 2025   138,004      
Stock-based compensation 48,971 48,971
Issuance of common stock pursuant to equity line of credit, net 2,060,312 $ 277 2,060,035
Issuance of common stock pursuant to equity line of credit, net, shares   277,000      
Issuance of common stock upon conversion of convertible notes 112 $ 112
Issuance of common stock upon conversion of convertible notes, shares   111,608      
Transition to additional paid-in capital upon conversion of convertible notes 1,357,253 1,357,253
Round up of fractional shares resulting from the reverse stock splits
Round up of fractional shares resulting from the reverse stock splits, shares   247      
Disposition of Nobility Healthcare 4,343,217 1,885,802 2,457,415
Net income (loss) (5,885,315) (5,885,315)
Balance at Mar. 31, 2026 4,294,506 $ 527 151,906,315 (147,612,336)
Balance, shares at Mar. 31, 2026   526,860      
Balance at Dec. 31, 2025 2,369,956 $ 138 148,440,056 (1,885,802) (144,184,436)
Balance, shares at Dec. 31, 2025   138,004      
Transition to additional paid-in capital upon conversion of convertible notes 1,357,253        
Net income (loss) (10,432,083)        
Balance at Jun. 30, 2026 2,275,454 $ 2,857 154,431,701 (152,159,104)
Balance, shares at Jun. 30, 2026   2,856,860      
Balance at Mar. 31, 2026 4,294,506 $ 527 151,906,315 (147,612,336)
Balance, shares at Mar. 31, 2026   526,860      
Stock-based compensation 63,615 63,615
Sale of common stock and pre-funded warrants, net of offering costs, shares   300,000      
Issuance of common stock pursuant to equity line of credit, net 2,080,101 $ 2,330 2,077,771
Issuance of common stock pursuant to equity line of credit, net, shares   2,330,000      
Litigation settlement 384,000 384,000
Net income (loss) (4,546,768) (4,546,768)
Balance at Jun. 30, 2026 $ 2,275,454 $ 2,857 $ 154,431,701 $ (152,159,104)
Balance, shares at Jun. 30, 2026   2,856,860